[1] US APAD-TFAV. Diagnostic and statistical manual of mental disorders: DSM-5TM[M].5th ed.Codas,2013. [2] Elsabbagh M,Divan G,Koh YJ,et al. Global prevalence of autism and other pervasive developmental disorders[J]. Autism Res,2012,5(3):160-179. [3] Baio J,Wiggins L,Christensen DL,et al. Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2014[J]. MMWR Surveill Summ,2018,67(6):1-23. [4] Servadio M,Melancia F,Manduca A,et al. Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid[J]. Transl Psychiatry,2016,6(9):e902. [5] Nguyen QA,Horn ME,Nicoll RA. Distinct roles for extracellular and intracellular domains in neuroligin function at inhibitory synapses[J]. Elife,2016,5:e19236. [6] Hamzawy MA,El-Ghandour YB,Abdel-Aziem SH,et al. Leptin and camel milk abate oxidative stress status, genotoxicity induced in valproic acid rat model of autism[J]. Int J Immunopathol Pharmacol,2018,32:2058738418785514. [7] Wu H,Zhang Q,Gao J,et al. Modulation of sphingosine 1-phosphate (S1P) attenuates spatial learning and memory impairments in the valproic acid rat model of autism[J]. Psychopharmacology (Berl),2018,235(3):873-886. [8] Aran A,Eylon M,Harel M,et al. Lower circulating endocannabinoid levels in children with autism spectrum disorder[J]. Mol Autism,2019,10:2. [9] Karhson DS,Krasinska KM,Dallaire JA,et al. Plasma anandamide concentrations are lower in children with autism spectrum disorder[J]. Mol Autism,2018,9:18. [10] Siniscalco D,Sapone A,Giordano C,et al. Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders[J]. J Autism Dev Disord,2013,43(11):2686-2695. [11] Siniscalco D,Bradstreet JJ,Cirillo A,et al. The in vitro GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages[J]. J Neuroinflammation,2014,11:78. [12] Kerr DM,Gilmartin A,Roche M. Pharmacological inhibition of fatty acid amide hydrolase attenuates social behavioural deficits in male rats prenatally exposed to valproic acid[J]. Pharmacol Res,2016,113(Pt A):228-235. [13] Zamberletti E,Gabaglio M,Woolley-Roberts M,et al. Cannabidivarin treatment ameliorates autism-like behaviors and restores hippocampal endocannabinoid system and glia alterations induced by prenatal valproic acid exposure in rats[J]. Front Cell Neurosci,2019,13:367. [14] Neumeister A,Normandin MD,Pietrzak RH,et al. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study[J]. Mol Psychiatry,2013,18(9):1034-1040. [15] Melancia F,Schiavi S,Servadio M,et al. Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signalling[J]. Br J Pharmacol,2018,175(18):3699-3712. [16] Zou M,Li D,Li L,et al. Role of the endocannabinoid system in neurological disorders[J]. Int J Dev Neurosci,2019,76:95-102. [17] Kerr DM,Downey L,Conboy M,et al. Alterations in the endocannabinoid system in the rat valproic acid model of autism[J]. Behav Brain Res,2013,249:124-132. [18] Maier T,Guell M,Serrano L. Correlation of mRNA and protein in complex biological samples[J]. FEBS Lett,2009,583(24):3966-3973. |